Business Description
Cytokinetics Inc
NAICS : 325412
SIC : 2834
ISIN : US23282W6057
Share Class Description:
CYTK: Ordinary SharesTotal Employee Number:
673Compare
Compare
Traded in other countries / regions
CYTK.USAKK3A.Germany1CYTK.Italy Index Membership
Russell 2000Russell 3000 IPO Date
2004-04-29Description
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.92 | |||||
Equity-to-Asset | -0.09 | |||||
Debt-to-Equity | -7.32 | |||||
Debt-to-EBITDA | -1.68 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -0.37 | |||||
Beneish M-Score | -0.53 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -11.4 | |||||
3-Year EBITDA Growth Rate | -14.8 | |||||
3-Year EPS without NRI Growth Rate | -11.2 | |||||
3-Year FCF Growth Rate | -8.8 | |||||
3-Year Book Growth Rate | -67.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 32.15 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 121.53 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 22.96 | |||||
9-Day RSI | 31.58 | |||||
14-Day RSI | 36.43 | |||||
3-1 Month Momentum % | 3.44 | |||||
6-1 Month Momentum % | 27.69 | |||||
12-1 Month Momentum % | 112.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.66 | |||||
Quick Ratio | 6.66 | |||||
Cash Ratio | 6.43 | |||||
Days Inventory | 11.97 | |||||
Days Sales Outstanding | 63.91 | |||||
Days Payable | 948.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9 | |||||
Shareholder Yield % | -4.18 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 87.97 | |||||
Operating Margin % | -1046.12 | |||||
Net Margin % | -1321.12 | |||||
EBITDA Margin % | -1118.12 | |||||
FCF Margin % | -858.16 | |||||
OCF Margin % | -820.83 | |||||
ROA % | -61.36 | |||||
ROIC % | -116.93 | |||||
3-Year ROIIC % | -73.24 | |||||
ROC (Joel Greenblatt) % | -503.46 | |||||
ROCE % | -59.83 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 134.74 | |||||
EV-to-EBIT | -13.17 | |||||
EV-to-Forward-EBIT | -14.25 | |||||
EV-to-EBITDA | -13.38 | |||||
EV-to-Forward-EBITDA | -14.25 | |||||
EV-to-Revenue | 149.65 | |||||
EV-to-Forward-Revenue | 70.03 | |||||
EV-to-FCF | -17.44 | |||||
Price-to-GF-Value | 0.35 | |||||
Price-to-Median-PS-Value | 4.16 | |||||
Earnings Yield (Greenblatt) % | -7.59 | |||||
FCF Yield % | -5.79 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CYTK
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cytokinetics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 67.67 | ||
| EPS (TTM) ($) | -7.22 | ||
| Beta | 1.2117 | ||
| 3-Year Sharpe Ratio | 0.54 | ||
| 3-Year Sortino Ratio | 1.9 | ||
| Volatility % | 61.61 | ||
| 14-Day RSI | 36.43 | ||
| 14-Day ATR ($) | 2.740455 | ||
| 20-Day SMA ($) | 76.8405 | ||
| 12-1 Month Momentum % | 112.72 | ||
| 52-Week Range ($) | 35.22 - 88.31 | ||
| Shares Outstanding (Mil) | 139.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cytokinetics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cytokinetics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-26 | In 181 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-24 16:30 | In 180 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-24 16:00 | In 180 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 16:30 | In 69 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 16:00 | In 69 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | 78.85 (-0.72%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 16:00 | 78.85 (-0.72%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-08 09:20 | 71.48 (-1.87%) | ||
| Guidance call for 2026 | 2026-06-03 08:10 | 70.91 (-2.15%) | ||
| General meeting for 2026 | 2026-05-27 10:00 | 76.29 (-0.93%) |
Show
Entries
Cytokinetics Inc Frequently Asked Questions
What is Cytokinetics Inc(CYTK)'s stock price today?
The current price of CYTK is $72.09. The 52 week high of CYTK is $88.31 and 52 week low is $35.22.
When is next earnings date of Cytokinetics Inc(CYTK)?
The next earnings date of Cytokinetics Inc(CYTK) is 2026-11-05 Est..
Does Cytokinetics Inc(CYTK) pay dividends? If so, how much?
Cytokinetics Inc(CYTK) does not pay dividend.
Guru Commentaries on NAS:CYTK
2026 Q2
2Q2026global
Polaris Wealth Advisory Group, LLC
· 169 holdings
What the manager wrote
We added Cytokinetics to our portfolio, a U.S. biopharma company with FDA approval for Myqorzo for hypertrophic cardiomyopathy; Myqorzo is seen as superior to Bristol Myers Squibb’s Camzyos, offering better symptom relief with simpler dosing.
Press Release
Articles on Cytokinetics Inc
Headlines
See More- 1
Aug 28, 2026
Cytokinetics posts full data from late-stage trial for lead drug in non-obstructive HCM
Seeking Alpha • 9:23am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers